Jon Faiz Kayyem, a director of Inhibrx, Inc. (NASDAQ:INBX – Get Rating) sold 9,500 shares of the company’s stock in a transaction on Friday, October 21. The shares sold at an average price of $30.13 for a total value of $286,235.00. Following the transaction, the Director now owns 3,252,801 shares of the Company, valued at $98,006,894.13. The sale was disclosed in a document filed with the SEC, which is available through the SEC’s website.
Inhibrx price performance
INBX traded down $0.12 on Monday to hit $30.88. The company had a trading volume of 471,905 shares compared to its average volume of 486,763. The company has a leverage ratio of 4.16, a current ratio of 7.50 and a quick ratio of 7.50. Inhibrx, Inc. has a 1 year low of $7.67 and a 1 year high of $47.90. The stock has a 50-day moving average price of $21.01 and a 200-day moving average price of $17.50.
Inhibrx (NASDAQ:INBX – Get Rating) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.13). The company had revenue of $0.71 million for the quarter, compared to analyst estimates of $0.90 million. Inhibrx had a negative net margin of 1,575.91% and a negative return on equity of 430.07%. On average, equities analysts are forecasting that Inhibrx, Inc. will report -3.38 earnings per share for the year to date.
Wall Street analysts forecast growth
A number of equity analysts recently commented on the company. Evercore ISI increased its target price on Inhibrx to $60.00 from $54.00 and gave the company a rating of “Outperform” in a report on Wednesday, October 5th. Credit Suisse Group lowered its target price on Inhibrx to $48.00 in a report on Monday, August 15. Finally, JMP Securities reiterated a “buy” rating and price target of $40.00 on shares of Inhibrx in a research report on Wednesday, October 5th.
Institutional investors rely on Inhibrx
Hedge funds have recently changed their stock holdings. Point72 Hong Kong Ltd increased its holding in Inhibrx shares by 154.6% during the second quarter. Point72 Hong Kong Ltd now owns 2,879 shares of the company, valued at $33,000, having purchased a further 1,748 shares during the period. Quantbot Technologies LP increased its holding in Inhibrx stock by 158.3% during the first quarter. Quantbot Technologies LP now owns 3,100 shares of the company, valued at $69,000, having purchased an additional 1,900 shares during this period. Legal & General Group Plc increased its holding in Inhibrx shares by 52.7% in the second quarter. Legal & General Group Plc now owns 8,383 shares of the company, valued at $95,000, after purchasing a further 2,892 shares during the period. Graham Capital Management LP acquired a new stake in Inhibrx stock valued at $203,000 during the first quarter. Finally, HighTower Advisors LLC acquired a new stake in Inhibrx stock valued at $223,000 during the first quarter. 67.27% of the shares are owned by institutional investors and hedge funds.
Inhibrx, Inc, a clinical-stage biotechnology company, is focused on developing a pipeline of novel biological therapeutic candidates. The Company’s therapeutic candidates include INBRX-109, a tetravalent death receptor 5 agonist in Phase 2 clinical trials for the treatment of cancers such as chondrosarcoma, mesothelioma and pancreatic adenocarcinoma; INBRX-105, a tetravalent programmed death ligand 1 conditional agonist and a 4-1BB conditional agonist in Phase 1 clinical trials for the treatment of patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1-antitrypsin (AAT)-Fc fusion protein therapeutic candidate that is in Phase 1 clinical trials for use in treating patients with AAT deficiency.
This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide readers with the fastest, most accurate reporting. This story was reviewed by the MarketBeat editorial team before publication. Please send questions or comments about this story to [email protected].
Before you consider Inhibrx, here’s what you should hear.
MarketBeat tracks Wall Street’s best-in-class, top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market takes hold… and Inhibrx didn’t make the list.
While Inhibrx currently has a buy rating among analysts, top analysts believe these five stocks are better buys.
Check out the five stocks here